Aruvant to Present at Investor and Scientific Conferences in October
NEW YORK and BASEL, Switzerland, Sept. 29, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced it will present at multiple conferences in...
One-time Gene Therapy for Sickle Cell Disease
Aruvant is developing ARU-1801, a one-time, potentially curative gene therapy for sickle cell disease andβ-thalassemia. In an ongoing clinical phase 1/2 study, ARU-1801, administered with only reduced intensity conditioning,has provided stable reductions in disease...
Aruvant Appoints Dr. Palaniappan as Chief Technology Officer
Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than 30 compounds including gene therapies for rare diseasesDr. Palaniappan will lead the manufacturing...
Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer
Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell disease administered with reduced intensity conditioning Most recently as head of clinical...
Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease
ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity...
Aruvant Receives FDA Rare Pediatric Disease Designation for ARU-1801 for the Treatment of Sickle Cell Disease
ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity...
Aruvant Appoints William Chou as Chief Executive Officer
Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe and Asia Chou previously led the development and approval of Kymriah® for diffuse large B-cell lymphoma He...
Aruvant Sciences Presents Data from Ongoing Clinical Study of Lentiviral Gene Therapy RVT-1801 for Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology
Two patients have been administered RVT-1801 in conjunction with reduced intensity conditioning regimens Both patients exhibit evidence of sustained, stable, genetically-modified cells in blood and bone marrow over a year after receiving treatment BASEL, NEW YORK, and...